An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A company called Ozari Health has launched a nationwide telehealth service that offers compounded versions of semaglutide and tirzepatide by subscription, with prices starting at about $86 per month. That means people can sign up online, have a virtual visit with a clinician, and get these peptide-based prescriptions filled and shipped to them rather than visiting an in-person clinic. The announcement is a business move and not a clinical trial result. Semaglutide and tirzepatide are drugs that act like natural hormones in the gut that help reduce appetite and slow stomach emptying. Semaglutide is the active ingredient in brand drugs like Ozempic and Wegovy. Tirzepatide is newer and works on two hormone systems at once. Both are used under doctor supervision to help with weight loss and with blood sugar control in diabetes. When we say “compounded,” that usually means a pharmacy mixes doses specifically for an individual rather than using a factory-made branded product. What this business news actually shows is that there is growing demand for easier, cheaper access to these medications, and a company is responding by offering an online model and lower-cost compounded versions. The announcement doesn’t present new medical research or offer proof that the compounded products work the same as branded ones. It also doesn’t say how the telehealth assessments will be handled, what specific doses will be offered, or publish safety or outcome data. The price point — starting at $86/month — is what the company advertises, but actual cost to a patient could vary depending on monitoring, labs, or shipping. Why this matters is practical: these drugs have been in high demand because many people seek weight loss options, and in-person clinics or brand-name prescriptions can be expensive or have long waits. An online, subscription model could make access easier and cheaper for people who already have a prescription for semaglutide or tirzepatide or who qualify medically in a telehealth visit. It could also increase the number of people using these therapies, for better or worse, because convenience lowers the barrier to starting treatment. There are important caveats and risks. Compounded medications are not the same as FDA-approved brand products and may have different quality controls. Telehealth assessments may miss conditions that would be caught in-person. Both semaglutide and tirzepatide can cause side effects like nausea, vomiting, low blood sugar (especially in people on other diabetes drugs), and rare but serious risks discussed with a clinician, such as pancreatitis. These drugs are prescription medications; they should be used under medical supervision with appropriate monitoring. Finally, a company press announcement is not independent evidence of safety or effectiveness, so people should ask questions, check credentials, and consider consulting their regular doctor before switching to a telehealth-compounded service. Bottom line: A new telehealth service is offering cheaper, compounded semaglutide and tirzepatide subscriptions nationwide, which could increase access but raises questions about quality, safety, and medical oversight.
Source: markets.businessinsider.com